Form: 8-K

Current report

May 21, 2026

false 0000704440 0000704440 2026-05-19 2026-05-19 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported)   May 19, 2026

 

KORU Medical Systems, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware 0-12305 13-3044880
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)

 

100 Corporate Drive, Mahwah, NJ 07430
(Address of principal executive offices) (Zip Code)

 

Registrant’s telephone number, including area code   (845) 469-2042

 

not applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

[_]  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

[_]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

[_]  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

[_]  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading symbol(s) Name of each exchange on which registered
common stock, $0.01 par value KRMD The Nasdaq Stock Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company  [_]

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  [_]

 


 

Item 5.07.        Submission of Matters to a Vote of Security Holders.

 

Set forth below are the voting results from the 2026 Annual Meeting of Shareholders held on May 19, 2026:

 

Total shares voted: 36,678,784

 

Proposal 1: Election of Directors

 

The nominees for director set forth under “Nominees” below were elected to the Company’s board of directors.

 

  Number of Shares
Nominees For Against Abstain Broker Non-Vote
R. John Fletcher 25,202,422 647,041 8,671 10,820,650
Robert A. Cascella 25,635,760 213,703 8,671 10,820,650
Donna French 25,801,738 41,675 14,721 10,820,650
Joseph M. Manko, Jr. 25,794,709 54,754 8,671 10,820,650
Shahriar (Shar) Matin 25,800,075 41,322 16,737 10,820,650
Linda Tharby 25,446,988 402,677 8,469 10,820,650
Edward Wholihan 25,804,371 44,791 8,972 10,820,650

 

Proposal 2: Approval of an amendment to the 2024 Omnibus Equity Incentive Plan to increase the available number of shares.

 

The Company’s shareholders approved the amendment to the 2024 Omnibus Equity Incentive Plan to increase the available number of shares.

 

  For Against Abstain Broker Non-Vote
Number of Shares 25,018,973 826,145 13,016 10,820,650

 

Proposal 3: Advisory approval of the compensation of the Company’s executive officers.

 

The Company’s shareholders, on an advisory basis, approved the compensation of the Company’s executive officers.

 

  For Against Abstain Broker Non-Vote
Number of Shares 25,723,379 91,649 43,106 10,820,650

 

Proposal 4: Advisory approval of the frequency of future votes on executive compensation.

 

The Company’s shareholders, on an advisory basis, approved the frequency of future votes on executive compensation to be every one year.

 

  1 Year 2 Years 3 Years Abstain Broker Non-Vote
Number of Shares 24,865,692 61,741 916,055 14,646 10,820,650

 

Proposal 5: Ratification of the appointment of independent registered accountants for the 2026 fiscal year.

 

The Company’s shareholders ratified the appointment of Cherry Bekaert LLP as the company’s independent registered public accountants for the 2026 fiscal year.

 

  For Against Abstain
Number of Shares 36,500,510 19,629 158,645

 

- 2 -


 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  KORU Medical Systems, Inc.
(Registrant)
     
Date:  May 19, 2026 By: /s/ Linda Tharby
  Linda Tharby
Chief Executive Officer

 

- 3 -